STL Volume 24 Number 3
Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review
This review examines the clinical trials of topical diacerein and its role in Epidermolysis Bullosa Simplex. Diacerein cream was recently US FDA-approved in May 2018 for treatment of patients with EBS.
Update on the Management of Vitiligo
Vitiligo is a psychosocially debilitating disease requiring a multidisciplinary approach to treatment. Patients should be made aware of all of the options available geared at repigmentation and depigmentation prior to formulating a treatment plan.
Update on Drugs & Devices: May – June 2019
Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).
